2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
07/19/18AVEO Oncology Issues Statement Regarding Revised TIVO-3 Trial Guidance
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 19, 2018-- AVEO Oncology (NASDAQ: AVEO) today issued the following statement regarding its recently revised guidance on the timing of topline data from the TIVO-3 study, its Phase 3 trial of tivozanib as a third-line treatment for advanced renal cell carcinoma. “The Company expects to report topline results from the TIVO-3 study in the fourth quarter of 2018, approximately 6-8 weeks after the trial r... 
Printer Friendly Version
06/25/18AVEO Oncology Added to the Russell 2000, Russell 3000, and Russell Microcap Indexes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 25, 2018-- AVEO Oncology (NASDAQ: AVEO) today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective after the U.S. market closed on Friday, June 22, 2018 as part of FTSE’s annual reconstitution. “We believe that inclusion in the widely referenced Russell U.S. Indexes reflects the significant progress we have made as a Company in the last year, ... 
Printer Friendly Version
05/31/18AVEO Oncology to Present at the Jefferies 2018 Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 31, 2018-- AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Jefferies 2018 Healthcare Conference in New York on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be... 
Printer Friendly Version
05/08/18AVEO Reports First Quarter 2018 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 8, 2018-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2018 and provided a business update. “We continue to work toward reporting topline results from our Phase 3 TIVO-3 Study, which we now anticipate will occur in the third quarter of 2018. We are working closely with our contract research organization (CRO) to shorten the time required to do the data cl... 
Printer Friendly Version
03/26/18AVEO Oncology to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 26, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: Needham & Company’s 17th Annual Healthcare Conference on Wednesday, March 28, 2018 at 8:00 a.m. Eastern Time. The conference is being held at the Westin Grand Central Hotel in New York, New York. H.C.... 
Printer Friendly Version
03/21/18AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC
Results Published in the European Journal of Cancer CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 21, 2018-- AVEO Oncology (NASDAQ: AVEO) today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib (FOTIVDA®) as second-line treatment in advanced renal cell carcinoma (aRCC), in the European Journal of Cancer. The publication, titled “Efficacy of Tivozanib Treatment after Sorafenib in Patie... 
Printer Friendly Version
03/13/18AVEO Reports Full Year 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2018-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2017 and provided a business update. “Last year was one of major progress for AVEO, with highlights including the first commercial launch of tivozanib (FOTIVDA®); the completion of the enrollment for TIVO-3, our U.S. registration study; the receipt of promising results from the Phase 1b/2 TiNivo comb... 
Printer Friendly Version
03/06/18AVEO Oncology to Present at the Cowen and Company 38th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2018-- AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:40 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the... 
Printer Friendly Version
02/12/18AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA® (tivozanib) as First Line Treatment for Advanced Renal Cell Carcinoma
Recommendation Triggers $2M Milestone Payment from EUSA to AVEO CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 12, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending FOTIVDA® (tivozanib) for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC). In the European Union, Norway and Ic... 
Printer Friendly Version
02/10/18AVEO Oncology and EUSA Pharma Announce Encouraging Preliminary Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
Data Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--Feb. 10, 2018-- AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the presentation of preliminary results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA®) in combination with intravenous (IV) nivolumab ... 
Printer Friendly Version
02/07/18AVEO Oncology to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2018-- AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 10:00 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel. RBC Capital Markets He... 
Printer Friendly Version
02/01/18AVEO Announces Appointment of John H. Johnson to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- AVEO Oncology (NASDAQ: AVEO) today announced the appointment of John H. Johnson to the Company’s Board of Directors. Mr. Johnson brings to AVEO over three decades of experience in the biotechnology and pharmaceuticals industries, having held commercial and executive management roles at leading global corporations that have a focus on oncology, including Johnson & Johnson, Eli Lilly & Company, ImCl... 
Printer Friendly Version
01/19/18AVEO Oncology Announces Presentation of Data from Phase 1b/2 Study of Tivozanib in Patients with Advanced Hepatocellular Carcinoma
Poster Presentation Delivered at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 19, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA® (tivozanib), a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, in patients with advanced, unre... 
Printer Friendly Version
01/04/18AVEO Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 11:30 a.m. Pacific Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of t... 
Printer Friendly Version
01/02/18AVEO Oncology Announces Refinanced Debt Facility
Provides Approximately $12.1M in Additional Cash Flow Over 2018-19 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that it has completed the refinancing of its existing $20.0 million debt facility with Hercules Capital, Inc. and its affiliates, the terms of which enable approximately an additional $12.1 million in cash flow over 2018 and 2019, when compared to the prior loan. The new $20.0 million facilit... 
Printer Friendly Version